0001397702-23-000046.txt : 20230623 0001397702-23-000046.hdr.sgml : 20230623 20230623160759 ACCESSION NUMBER: 0001397702-23-000046 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230621 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230623 DATE AS OF CHANGE: 20230623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Silk Road Medical Inc CENTRAL INDEX KEY: 0001397702 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 208777622 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38847 FILM NUMBER: 231037739 BUSINESS ADDRESS: STREET 1: 1213 INNSBRUCK DR. CITY: SUNNYVALE STATE: CA ZIP: 94089-2918 BUSINESS PHONE: 6505669060 MAIL ADDRESS: STREET 1: 1213 INNSBRUCK DR. CITY: SUNNYVALE STATE: CA ZIP: 94089-2918 8-K 1 silk-20230621x8k.htm 8-K silk-20230621x8k
false--12-31000139770200013977022023-06-212023-06-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 8-K

____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2023

____________________________

SILK ROAD MEDICAL, INC.

(Exact name of registrant as specified in its charter)

____________________________

Delaware

001-38847

20-8777622

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

1213 Innsbruck Drive

Sunnyvale, California

94089

(Address of principal executive offices)

(Zip Code)

(408) 720-9002

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.001 Per Share

SILK

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.03.Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At an Annual Meeting of Stockholders of Silk Road Medical, Inc. (the “Company”) held on June 21, 2023, the Company’s stockholders adopted and approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to eliminate or limit the personal liability of certain officers of the Company to the extent permitted by recent amendments to Delaware law (the “Charter Amendment”). A description of the Charter Amendment can be found in “Proposal No. 3. Approval of an Amendment to Our Certificate of Incorporation to Eliminate or Limit the Personal Liability of Officers” in the Company’s definitive proxy statement for the Company’s 2023 Annual Meeting of Stockholders filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2023. The Charter Amendment became effective upon the filing of a Certificate of Amendment to Amended and Restated Certificate of Incorporation of Silk Road Medical, Inc. (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on June 21, 2023.

The foregoing description of the Charter Amendment is not complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07.Submission of Matters to a Vote of Security Holders.

The Company held an Annual Meeting of Stockholders on June 21, 2023 (the “Annual Meeting”).

As of the close of business on April 24, 2023, the record date for the Annual Meeting, there were 38,727,141 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. Each share of common stock was entitled to one vote. Stockholders holding an aggregate of 35,403,960 shares of common stock entitled to vote at the Annual Meeting, representing 91.41% of the Company’s outstanding shares of common stock as of the record date, and which constituted a quorum thereof, were present in person or represented by proxy at the Annual Meeting.

At the Annual Meeting, the Company’s stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the SEC on April 28, 2023.

The final results of such stockholder voting on each proposal brought before the Annual Meeting are set forth below:

Proposal No. 1 - Election of Directors. The three Class I and two Class III director nominees proposed by the Board of Directors of the Company were elected to serve as members of the Board of Directors until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified by the following final voting results:

Votes For

Votes Withheld

Broker Non-Votes

Class I Director Nominees

Rick D. Anderson

32,437,130

1,740,452

1,226,378

Jack W. Lasersohn

31,582,599

2,594,983

1,226,378

Erica J. Rogers

33,787,354

390,228

1,226,378

Class III Director Nominees

Elizabeth H. Weatherman

23,943,783

10,233,799

1,226,378

Donald J. Zurbay

27,214,958

6,962,624

1,226,378


Proposal No. 2 - Advisory Vote to Approve Named Executive Officer Compensation. The Company’s stockholders did not approve the advisory vote on the compensation of the Company’s executive officers named in the Company’s definitive proxy statement. The following are final voting results:

Votes For

Votes Against

Votes Abstained

Broker Non-Votes

13,904,626

20,247,589

25,367

1,226,378

Proposal No. 3 - Approval of an Amendment to Our Certificate of Incorporation to Eliminate or Limit the Personal Liability of Officers. The Company’s stockholders adopted and approved the Charter Amendment by the following final voting results:

Votes For

Votes Against

Votes Abstained

Broker Non-Votes

29,708,779

3,623,071

845,732

1,226,378

Proposal No. 4 - Ratification of Appointment of Independent Registered Public Accounting Firm. The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, was approved by the Company’s stockholders by the following final voting results:

Votes For

Votes Against

Votes Abstained

Broker Non-Votes

35,191,470

190,320

22,170

0

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.

Description

3.1

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Silk Road Medical, Inc. (filed herewith)

104

Cover Page Interactive Data File (formatted as inline XBRL)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILK ROAD MEDICAL, INC.

Date: June 23, 2023

By:

/s/ Kevin M. Klemz

Name:

Kevin M. Klemz

Title:

Executive Vice President, Chief Legal Officer and Secretary

EX-3.1 2 silk-20230621xex3_1.htm EX-3.1 Exhibit 31 Amended and Restated COI

Delaware

The First State

Page 1







 









I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “SILK ROAD MEDICAL, INC.”, FILED IN THIS OFFICE ON THE TWENTY-FIRST DAY OF JUNE, A.D. 2023, AT 6:34 O`CLOCK P.M.

































Picture 2

 



 





 

 



Picture 1

 





 

4319923 8100

Authentication: 203598752

SR# 20232820521

Date: 06-22-23

You may verify this certificate online at corp.delaware.gov/authver.shtml



 


 

CERTIFICATE OF AMENDMENT TO

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF

SILK ROAD MEDICAL, INC.



Pursuant to Section 242 of the General Corporation Law of the State of Delaware



Silk Road Medical, Inc. (hereinafter called the "Corporation"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows:



l.    The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by replacing Section 8.1 of Article VIII so that it would state in its entirety as follows:



"8.1 Limitation of Personal Liability. To the fullest extent permitted by the DGCL, as it presently exists or may hereafter be amended from time to time, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended."



2.  The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by replacing the final paragraph of Section 8.2 of Article VIII so that it would state in its entirety as follows:



"Any repeal or amendment of this Article VIII by the stockholders of the Corporation or by changes in law, or the adoption of any other provision of this Certificate of Incorporation inconsistent with this Article VIII will, unless otherwise required by law, be prospective only (except to the extent such amendment or change in law permits the Corporation to further limit or eliminate the liability of directors or officers) and shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of such repeal or amendment or adoption of such inconsistent provision with respect to acts or omissions occurring prior to such repeal or amendment or adoption of such inconsistent provision."



3.  The foregoing amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.



IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to Amended and Restated Certificate of  Incorporation to be executed this 21st day of June, 2023, in its name and on its behalf by its Executive Vice President, Chief Legal Officer and Secretary, pursuant to Section 103 of the General Corporation Law of the State of Delaware.





 

 



SILK ROAD MEDICAL, INC.



 



By: /s/ Kevin M. Klemz



Name: Kevin M. Klemz



Title: Executive Vice President, Chief Legal Officer and Secretary







 

State of Delaware

 

Secretary of State

 

Division of Corporations

 

Delivered 06:34 PM 06/21/2023

 

FILED 06:34 PM 06121/2023

 

SR 20232820521 - File Number 4319923

 




GRAPHIC 3 silk-20230621xex3_1g001.jpg GRAPHIC begin 644 silk-20230621xex3_1g001.jpg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end GRAPHIC 4 silk-20230621xex3_1g002.jpg GRAPHIC begin 644 silk-20230621xex3_1g002.jpg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end EX-101.SCH 5 silk-20230621.xsd EX-101.SCH 00090 - Document - Cover Pagelink:presentationLinklink:calculationLinklink:definitionLink EX-101.LAB 6 silk-20230621_lab.xml EX-101.LAB Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Soliciting Material Pre-Commencement Tender Offer Pre-Commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Amendment Flag Current Fiscal Year End Date EX-101.PRE 7 silk-20230621_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page
Jun. 21, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 21, 2023
Entity Registrant Name SILK ROAD MEDICAL, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38847
Entity Tax Identification Number 20-8777622
Entity Address, Address Line One 1213 Innsbruck Drive
Entity Address, City or Town Sunnyvale
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94089
City Area Code 408
Local Phone Number 720-9002
Written Communications false
Soliciting Material false
Pre-Commencement Tender Offer false
Pre-Commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol SILK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001397702
Amendment Flag false
Current Fiscal Year End Date --12-31
XML 9 silk-20230621x8k_htm.xml IDEA: XBRL DOCUMENT 0001397702 2023-06-21 2023-06-21 false --12-31 0001397702 8-K 2023-06-21 SILK ROAD MEDICAL, INC. DE 001-38847 20-8777622 1213 Innsbruck Drive Sunnyvale CA 94089 408 720-9002 false false false false Common Stock, Par Value $0.001 Per Share SILK NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Cover Page Sheet http://silkroadmed.com/role/DocumentCoverPage Cover Page Cover 1 false false All Reports Book All Reports silk-20230621x8k.htm silk-20230621.xsd silk-20230621_lab.xml silk-20230621_pre.xml silk-20230621xex3_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "silk-20230621x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "silk-20230621x8k.htm" ] }, "labelLink": { "local": [ "silk-20230621_lab.xml" ] }, "presentationLink": { "local": [ "silk-20230621_pre.xml" ] }, "schema": { "local": [ "silk-20230621.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "silk", "nsuri": "http://silkroadmed.com/20230621", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "silk-20230621x8k.htm", "contextRef": "Duration_6_21_2023_To_6_21_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://silkroadmed.com/role/DocumentCoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "silk-20230621x8k.htm", "contextRef": "Duration_6_21_2023_To_6_21_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://silkroadmed.com/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001397702-23-000046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001397702-23-000046-xbrl.zip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end